Search for Clinical Trial Results

Sponsored By

Inflammatory Breast Neoplasms - 25 Studies Found

Status Study
Recruiting Study Name: Case-Control Study of Inflammatory Breast Cancer in North Africa
Condition: Inflammatory Breast Cancer
Date: 2008-11-18
Recruiting Study Name: Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer
Date: 2011-05-25
Interventions:
  • Biological: Bevacizumab During
Recruiting Study Name: Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer (IBC)
Date: 2016-08-09
Interventions:
  • Drug: Ruxolitinib 15 or 20 mg,
Completed Study Name: Establishing an Inflammatory Breast Cancer Registry
Condition: Inflammatory Breast Cancer
Date: 2006-06-19
Recruiting Study Name: Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Condition: Inflammatory Breast Carcinoma
Date: 2013-06-25
Interventions:
  • Drug: 89Zr-bevacizumab 89Zr-be
Completed Study Name: Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia
Condition: Inflammatory Breast Cancer
Date: 2006-06-23
Completed Study Name: Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer
Date: 2014-12-14
Interventions:
  • Drug: Docetaxel
  • Drug: Cyclophosphamide
Recruiting Study Name: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Condition:
  • Inflammatory Breast Cancer
  • Human Epidermal Growth Factor 2 Nega
    Date: 2015-12-02
    Interventions:
    • Drug: Eribulin administered IV
Not yet recruiting Study Name: Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Condition:
  • HER2/Neu Negative
  • Recurrent Inflammatory Breast Carcinoma

    • Date: 2016-09-02
    Interventions:
    • Biological: Ipilimumab Given I
Recruiting Study Name: A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy
Condition:
  • Inflammatory Breast Cancer
  • Malignant Neoplasm of Breast
    • Date: 2016-11-21
    Interventions: Drug: Pembrolizumab Pembrolizumab 200 mg administered on day 1 of each 3-week cycle as approximately 30
Next >>>